3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
53
NETWORK
7
NIH
6
OTHER_GOV
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
282
Carboplatin
217
Cisplatin
147
Gemcitabine
146
Paclitaxel
142
Bevacizumab
116
Pemetrexed
114
Docetaxel
101
Oxaliplatin
79
durvalumab
78
Dexamethasone
77
Fluorouracil
76
atezolizumab
75
Nivolumab
75
Cyclophosphamide
74
130-nm albumin-bound paclitaxel
71
Fulvestrant
70
Capecitabine
64
Cetuximab
63
Injections
62
Leucovorin
60
Rituximab
55
fludarabine
50
Lenalidomide
50
venetoclax
44
Prednisone
43
Irinotecan
42
Letrozole
40
enzalutamide
39
tislelizumab
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Surgical Procedures, Operative
×
90 days
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled
NCT06295809
2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
46 enrolled